Intouch Solutions

JULY 27, 2021

This new tactic illustrates the lengths to which payers are going to increase the use of biosimilars, and it previews what we can expect when Humira faces biosimilar competition in 2023. We can also expect other health plans and pharmacy benefit managers (PBMs) to make this approach part of their own toolkits if it proves to be successful.

Drugs 52

Drugs Marketing Vaccination Vaccine 52

The Pharma Data

MAY 5, 2021

AbbVie’s Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along ( Fierce ). . Startup sets out to tackle the gene therapy manufacturing crisis ( Endpoints ). Esker, a new biotech startup, launches with plans to make targeted immune drugs ( BioPharma Dive ).

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52

World of DTC Marketing

JUNE 16, 2021

The pharma industry has been riding a wave of public approval since they developed a vaccine to fight COVID-19, but that goodwill is going to be short lived thanks, in part, to the $56,000 price tag of Biogen’s new drug and insulin that too many people still can’t afford. And it’s not because the drugs are getting better.

Drugs 180

Drugs Branding Medicine Insulin 180